Physician profile
Philip G Kies
NPI 1508819244
$2,405.82
in general payments reported to CMS, 2019-2025
20 companies · $522 in 2025
The $522 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $34.41 · 2021: $96.77 · 2022: $468 · 2023: $499 · 2024: $262 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $403.28 | 2022-2025 | Rocklatan |
| Abbvie INC. | $300.45 | 2022-2025 | |
| Shire North American Group INC | $267.00 | 2019 | |
| Biotissue Holdings INC. | $195.69 | 2023-2024 | |
| Harrow Eye, LLC | $177.46 | 2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $143.81 | 2019-2021 | |
| Rxsight INC | $141.43 | 2023 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sun Pharmaceutical Industries INC. | $123.67 | 2023-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.03 | 2019-2021 | |
| Dompe US, INC. | $111.65 | 2025 | Oxervate |
| Halozyme INC | $91.87 | 2020-2025 | Hylenex Recombinant |
| Ocular Therapeutix, INC. | $84.29 | 2024 | Dextenza |
| Allergan, INC. | $65.82 | 2021-2022 | |
| Omeros Corporation | $44.37 | 2020-2021 | |
| Amgen INC. | $32.26 | 2025 | Tepezza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $27.33 | 2019 | |
| Astellas Pharma US INC | $26.60 | 2025 | Izervay |
| Bausch & Lomb Americas INC. | $19.83 | 2023 | Vyzulta |
| Thea Pharma INC. | $19.73 | 2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $17.25 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Kies listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.